All To Play For: CAR-T Specialist Celyad’s Big Year

Celyad’s leadership team talks to Scrip about the critical nature of the coming months for its lead cancer therapy product, and CAR-T market differentiation.

Speech bubble
• Source: Shutterstock

This year is pivotal for the success of the Belgian biotech CAR-T company Celyad SA.

With a fresh CEO leading it into the next strategic age of the company, working to move into Phase II...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip